The receptor for advanced glycation end products (RAGE or AGER), a member of the immunoglobulin superfamily, is involved in pathologies such as atherosclerosis, micro- and macrovascular diseases, inflammatory diseases and diabetes. RAGE binds advanced glycation end products (AGE) produced by non-enzymatic glycation or glyoxidation of proteins, lipids and nucleic acids.
Synonyms: Anti-Advanced glycosylation end product-specific receptor; Anti-MGC22357; Anti-RAGE
MDL Number: MFCD06798857
Storage: -20C
Application: Anti-AGER (AB2) polyclonal antibody is used to tag advanced glycation end product receptor protein(s) for detection and quantitation by Western blotting and in cells and tissues by immunohistochemical (IHC) techniques. Anti-AGER (AB2) polyclonal antibody may be used to study the effects/roles of glycation and glyoxidation in cardiovascular disease and diabetes.
Biochem Physiol Actions: AGER mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. It is receptor for amyloid beta peptide.This gene encodes a member of the immunoglobulin superfamily of cell surface molecules. It is a receptor for various molecules, including the amyloidogenic form of serum amyloid A, amyloid-beta protein, members of the S100/calgranulin superfamily and advanced glycation end products. The gene lies within the major histocompatibility complex (MHC) class III region on chromosome 6. Alternative splicing results in two transcript variants encoding different isoforms.